Fezakinumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Fezakinumab
Monoclonal antibody
Type Whole antibody
Target IL-22
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6408H9873N1706O2016S44
Molar mass 143.87 kg/mol
 ☒N☑Y (what is this?)  (verify)

Fezakinumab is a human monoclonal antibody against interleukin-22,[1] designed for the treatment of psoriasis and rheumatoid arthritis.[2]

Research and development[edit]

Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer. Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis,[3] but data was not released. A small phase II trial of fezakinumab showed significant improvement in the Scoring Atopic Dermatitis (SCORAD) score for patients with severe atopic dermatitis.[4]

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab" (PDF). American Medical Association. Retrieved 2017-06-07. 
  2. ^ "Archived copy" (PDF). Archived from the original (PDF) on 2011-09-04. Retrieved 2012-09-25. 
  3. ^ "Living Medical eTextbook - Rheumatology - Projects In Knowledge - Rheumatoid Arthritis Edition Table of Contents - Emerging Parenteral Biologic Therapies for Rheumatoid Arthritis". Lmt.projectsinknowledge.com. p. 4. Retrieved 2017-06-07. 
  4. ^ Richardson, Brian. "Atopic dermatitis: fezakinumab shows benefit in severe disease". quantiamd.univadis.com. Aptus Health. Retrieved 24 January 2018. 

javascript:void(0);